Title: Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment
in Chinese Healthcare: An EVIDEM Framework Analysis
Version: 4 Date: 12 Jun 2024
Reviewer's report:
Thank you for inviting me to review this manuscript. The authors have utilized the EVIDEM
framework to assess the value contributions of vonoprazan (VPZ) and tegoprazan (TPZ),
revealing that VPZ offers a slightly superior value proposition compared to TPZ. These findings
could provide more information for healthcare decision-making.
The methodology employed in this study is its cornerstone, which has been the primary focus of
my evaluation. Nonetheless, upon reviewing the author’s responses to the previous reviewer’s
comments, it is evident that the methodological concerns have been adequately addressed.
Consequently, I have no additional comments.
Title: Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment
in Chinese Healthcare: An EVIDEM Framework Analysis
Version: 4 Date: 12 Jun 2024
Reviewer's report:
Thank you for inviting me to review this manuscript. The authors have utilized the EVIDEM
framework to assess the value contributions of vonoprazan (VPZ) and tegoprazan (TPZ),
revealing that VPZ offers a slightly superior value proposition compared to TPZ. These findings
could provide more information for healthcare decision-making.
The methodology employed in this study is its cornerstone, which has been the primary focus of
my evaluation. Nonetheless, upon reviewing the author’s responses to the previous reviewer’s
comments, it is evident that the methodological concerns have been adequately addressed.
Consequently, I have no additional comments.
Please review this paper.
user
Title: Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment
in Chinese Healthcare: An EVIDEM Framework Analysis
Version: 4 Date: 12 Jun 2024
Reviewer's report:
Thank you for inviting me to review this manuscript. The authors have utilized the EVIDEM
framework to assess the value contributions of vonoprazan (VPZ) and tegoprazan (TPZ),
revealing that VPZ offers a slightly superior value proposition compared to TPZ. These findings
could provide more information for healthcare decision-making.
The methodology employed in this study is its cornerstone, which has been the primary focus of
my evaluation. Nonetheless, upon reviewing the author’s responses to the previous reviewer’s
comments, it is evident that the methodological concerns have been adequately addressed.
Consequently, I have no additional comments.
assistant